These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 24011062)

  • 1. Combined use of rituximab and plasmapheresis pre-transplant increases post-transplant infections in renal transplant recipients with basiliximab induction therapy.
    Chung BH; Yun JT; Ha SE; Kim JI; Moon IS; Choi BS; Park CW; Kim YS; Yang CW
    Transpl Infect Dis; 2013 Dec; 15(6):559-68. PubMed ID: 24011062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly Sensitized Patients: Miami Transplant Institute Experience.
    Mattiazzi AD; Centeno A; Amador A; Fernandez-Bango C; Scowby CD; O'Rourke M; Hill-Matthie T; Patel R; Barrios F; Ruiz P; Chen L; Saghesima J; Ciancio G; Burke GW; Goldstein M; Chandar J; Contreras G; Roth D; Kupin W; Guerra G; Vianna R
    Clin Transpl; 2014; ():171-8. PubMed ID: 26281142
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined posttransplant prophylactic IVIg/anti-CD 20/plasmapheresis in kidney recipients with preformed donor-specific antibodies: a pilot study.
    Loupy A; Suberbielle-Boissel C; Zuber J; Anglicheau D; Timsit MO; Martinez F; Thervet E; Bruneval P; Charron D; Hill GS; Nochy D; Legendre C
    Transplantation; 2010 Jun; 89(11):1403-10. PubMed ID: 20386362
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus infection following renal transplantation in patients administered low-dose rituximab induction therapy.
    Nishida H; Ishida H; Tanaka T; Amano H; Omoto K; Shirakawa H; Shimizu T; Iida S; Toki D; Yamaguchi Y; Tanabe K
    Transpl Int; 2009 Oct; 22(10):961-9. PubMed ID: 19619177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kidney transplantation from HLA-incompatible live donors: Efficiency and outcome of 32 patients after desensitisation.
    Fernández C; Calvo M; Leite N; López A; Ferreiro T; Ribera R; Seijo R; Alonso Á
    Nefrologia; 2017; 37(6):638-645. PubMed ID: 28734583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study.
    Los-Arcos I; Len O; Perello M; Torres IB; Codina G; Esperalba J; Sellarés J; Moreso F; Seron D; Gavaldà J
    J Clin Virol; 2019 Jan; 110():45-50. PubMed ID: 30537648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation.
    Hachem RR; Chakinala MM; Yusen RD; Lynch JP; Aloush AA; Patterson GA; Trulock EP
    J Heart Lung Transplant; 2005 Sep; 24(9):1320-6. PubMed ID: 16143251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Living donor kidney transplantation in patients with donor-specific HLA antibodies enabled by anti-CD20 therapy and peritransplant apheresis.
    Klein K; Süsal C; Schäfer SM; Becker LE; Beimler J; Schwenger V; Zeier M; Schemmer P; Macher-Goeppinger S; Scherer S; Opelz G; Morath C
    Atheroscler Suppl; 2013 Jan; 14(1):199-202. PubMed ID: 23357165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in highly sensitized kidney transplant recipients.
    Munoz AS; Rioveros AA; Cabanayan-Casasola CB; Danguilan RA; Ona ET
    Transplant Proc; 2008 Sep; 40(7):2218-21. PubMed ID: 18790197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Induction treatment by combining immunoglobulins, plasmapheresis and rituximab in hypersensitive patients receiving cadaveric renal allograft].
    Rufino Hernández JM; Cabello Moya E; González-Posada JM; Hernández Marrero D; Pérez Tamajón L; Marrero Miranda D; García Rebollo S; Martín Urcuyo B; Rodríguez Hernández A; Franco Maside A; Barrios del Pino Y; Rodríguez Rodríguez R; Maceira Cruz B; Torres Ramírez A; Salido Ruiz E
    Nefrologia; 2010; 30(2):252-7. PubMed ID: 20098463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of intravenous immune globulin and rituximab for desensitization of highly HLA-sensitized patients awaiting kidney transplantation.
    Vo AA; Peng A; Toyoda M; Kahwaji J; Cao K; Lai CH; Reinsmoen NL; Villicana R; Jordan SC
    Transplantation; 2010 May; 89(9):1095-102. PubMed ID: 20110854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative Desensitization Improves Outcomes Among Crossmatch Positive Recipients of Deceased Donor Renal Transplants.
    Sharma A; King A; Kumar D; Behnke M; McDougan F; Kimball PM
    Prog Transplant; 2016 Jun; 26(2):157-61. PubMed ID: 27207404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P; Natrajan T; Jaganathan R
    Int Immunopharmacol; 2006 Dec; 6(13-14):1973-6. PubMed ID: 17161350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Desensitization with plasmapheresis and anti-Cd20 for ABO incompatible kidney transplantation from living donor: experience of a single center in Italy.
    Silvestre C; Furian L; Marson P; Tison T; Valente M; Marchini F; Rossi B; Bonfante L; Valerio F; Cozzi E; Rigotti P
    Transplant Proc; 2014 Sep; 46(7):2209-13. PubMed ID: 25242753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch.
    Riella LV; Safa K; Yagan J; Lee B; Azzi J; Najafian N; Abdi R; Milford E; Mah H; Gabardi S; Malek S; Tullius SG; Magee C; Chandraker A
    Transplantation; 2014 Jun; 97(12):1247-52. PubMed ID: 24854670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of the cellular pharmacodynamics of tacrolimus in renal transplant recipients treated with and without basiliximab.
    Sugiyama K; Isogai K; Horisawa S; Toyama A; Satoh H; Saito K; Nakagawa Y; Tasaki M; Takahashi K; Hirano T
    Cell Transplant; 2012; 21(2-3):565-70. PubMed ID: 22793066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.